Literature DB >> 25952944

A Meta-analytic Review of Non-specific Effects in Randomized Controlled Trials of Cognitive Remediation for Schizophrenia.

Rajiv Radhakrishnan1, Brian D Kiluk1, Jack Tsai2,3,4.   

Abstract

Cognitive remediation (CR) has been found to improve cognitive performance among adults with schizophrenia in randomized controlled trials (RCTs). However, improvements in cognitive performance are often observed in the control groups of RCTs as well. There has been no comprehensive examination of change in control groups for CR, which may inform trial methodology and improve our understanding of measured outcomes for cognitive remediation. In this meta-analysis, we calculated pre-post change in cognitive test performance within control groups of RCTs in 32 CR trials (n = 794 participants) published between 1970 and 2011, and examined the association between pre-post change and sample size, duration of treatment, type of control group, and participants' age, intelligence, duration of illness, and psychiatric symptoms. Results showed that control groups in CR trials showed small effect size changes (Cohen's d = 0.12 ± 0.16) in cognitive test performance over the trial duration. Study characteristics associated with pre-post change included participant age and sample size. These findings suggest attention to change in control groups may help improve detection of cognitive remediation effects for schizophrenia.

Entities:  

Keywords:  Cognitive remediation; Placebo; Randomized controlled trial; Schizophrenia

Mesh:

Year:  2016        PMID: 25952944      PMCID: PMC4637248          DOI: 10.1007/s11126-015-9362-6

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  14 in total

1.  The impact of cognitive remediation on psychiatric symptoms of schizophrenia.

Authors:  Nigel Bark; Nadine Revheim; Firdouse Huq; Vitaliy Khalderov; Zina Watras Ganz; Alice Medalia
Journal:  Schizophr Res       Date:  2003-10-01       Impact factor: 4.939

2.  Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program.

Authors:  Clare Reeder; Elizabeth Newton; Sophia Frangou; Til Wykes
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

3.  A meta-analysis of cognitive remediation in schizophrenia.

Authors:  Susan R McGurk; Elizabeth W Twamley; David I Sitzer; Gregory J McHugo; Kim T Mueser
Journal:  Am J Psychiatry       Date:  2007-12       Impact factor: 18.112

4.  Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; Ahmed Abbas Suleiman; An Vermeulen; Jing Liu; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

5.  Cognitive training in schizophrenia: golden age or wild west?

Authors:  Sophia Vinogradov; Melissa Fisher; Srikantan Nagarajan
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

6.  The role of randomization in clinical trials.

Authors:  P Armitage
Journal:  Stat Med       Date:  1982 Oct-Dec       Impact factor: 2.373

7.  REPYFLEC cognitive remediation group training in schizophrenia: Looking for an integrative approach.

Authors:  Aida Farreny; Jaume Aguado; Susana Ochoa; Elena Huerta-Ramos; Ferran Marsà; Raquel López-Carrilero; Vanessa Carral; Josep Maria Haro; Judith Usall
Journal:  Schizophr Res       Date:  2012-09-25       Impact factor: 4.939

8.  Effects of age and cognitive reserve on cognitive remediation therapy outcome in patients with schizophrenia.

Authors:  Dimitris Kontis; Vyv Huddy; Clare Reeder; Sabine Landau; Til Wykes
Journal:  Am J Geriatr Psychiatry       Date:  2013-03       Impact factor: 4.105

9.  Outcomes of patients completing and not completing cognitive therapy for depression.

Authors:  Jane Cahill; Michael Barkham; Gillian Hardy; Anne Rees; David A Shapiro; William B Stiles; Norman Macaskill
Journal:  Br J Clin Psychol       Date:  2003-06

Review 10.  Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

Authors:  Larry Alphs; Fabrizio Benedetti; W Wolfgang Fleischhacker; John M Kane
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-05       Impact factor: 5.176

View more
  4 in total

Review 1.  Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.

Authors:  John H Krystal; Chadi G Abdallah; Lynette A Averill; Benjamin Kelmendi; Ilan Harpaz-Rotem; Gerard Sanacora; Steven M Southwick; Ronald S Duman
Journal:  Curr Psychiatry Rep       Date:  2017-08-26       Impact factor: 5.285

Review 2.  Splitting Things Apart to Put Them Back Together Again: A Targeted Review and Analysis of Psychological Therapy RCTs Addressing Recovery From Negative Symptoms.

Authors:  Hamish J McLeod
Journal:  Front Psychiatry       Date:  2022-05-12       Impact factor: 5.435

3.  Role of learning potential in cognitive remediation: Construct and predictive validity.

Authors:  Charlie A Davidson; Jason K Johannesen; Joanna M Fiszdon
Journal:  Schizophr Res       Date:  2016-01-29       Impact factor: 4.939

4.  Computer-Assisted Cognitive Remediation in Schizophrenia: Efficacy of an Individualized vs. Generic Exercise Plan.

Authors:  Magdalena Bossert; Celina Westermann; Thomas M Schilling; Matthias Weisbrod; Daniela Roesch-Ely; Steffen Aschenbrenner
Journal:  Front Psychiatry       Date:  2020-09-16       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.